Azienda Ospedaliero-Universitaria Sant Andre
Rome, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the effects of a medication called Ocrelizumab in patients with Multiple Sclerosis (MS). Multiple Sclerosis is a condition that affects the brain and spinal cord, leading to a range of symptoms such as problems with vision, arm or leg movement, sensation, or balance. The study will compare two forms of administering Ocrelizumab: one is a subcutaneous injection, which means it is injected under the skin, and the other is an intravenous infusion, which means it is given directly into a vein.
The purpose of the study is to investigate how the body processes the subcutaneous form of Ocrelizumab compared to the intravenous form. Participants in the study will receive either the subcutaneous or intravenous form of the medication. The study will monitor various aspects such as the concentration of the medication in the blood, the number of new or enlarging lesions in the brain as seen on an MRI scan, and any side effects that may occur. The study will also look at the presence of antibodies, which are proteins made by the immune system, that might develop in response to the medication.
The study will take place over a period of time, with regular check-ups and assessments to ensure the safety and effectiveness of the treatment. Participants will have their blood tested, undergo MRI scans, and have their vital signs and laboratory test results monitored. The goal is to gather information on how well the subcutaneous form of Ocrelizumab works compared to the intravenous form, and to ensure it is safe for patients with Multiple Sclerosis.
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
6 criteria
712 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Rome, Italy
Poznan, Poland
Novy Hradec Kralove, Czechia
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication being studied for its effects on patients with Multiple Sclerosis (MS). In this trial, it is administered under the skin. The study aims to understand how this form of the medication is absorbed and processed by the body, and to compare its effectiveness and safety to the intravenous form.
is the same medication as the subcutaneous version, but it is given directly into a vein. This trial is comparing the two methods of administration to see if the subcutaneous form works as well as the intravenous form in treating MS. The study also looks at the safety and effects of the medication when given intravenously.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.